Granted Patent B2

US 12,508,262 · App. 17/246,577 · Granted Dec 30, 2025

Inventors: Jasbir S. Seehra (Lexington, MA); Jennifer Lachey (Lincoln, MA); Elissa Furutani (Belmont, MA)

Assignee: Keros Therapeutics, Inc.

A61K31/5025A61K9/0053A61K31/496A61K31/517A61P7/06

Abstract

Claims (11)

1 . A method of treating anemia associated with a myelodysplastic syndrome, anemia associated with β-thalassemia, Diamond Blackfan anemia, aplastic anemia, hemolytic anemia, or sickle cell anemia in a human subject, comprising administering to the subject a therapeutically effective amount of a small molecule ALK2 inhibitor of Formula I

or a pharmaceutically acceptable salt thereof, wherein:

R 1 is hydrogen or an optionally substituted substituent;

R 2 is optionally absent, hydrogen, or an optionally substituted substituent;

R 3 is hydrogen or an optionally substituted substituent;

R 4 is optionally absent, hydrogen, or an optionally substituted substituent;

R 5 is optionally absent, hydrogen, or an optionally substituted substituent;

R 138 is hydrogen or an optionally substituted substituent;

R 6 is independently one or more of hydrogen or an optionally substituted substituent; B 1 , is C or N; Y 1 is N or CR 139 , wherein R 139 is hydrogen or an optionally substituted substituent; Z 1 is N or CR 140 , wherein R 140 is hydrogen or an optionally substituted substituent; A 1 is C, N, O, C (O), S, SO, or SO 2 ; m is 0, 1, 2, or 3; n is 0, 1, 2, or 3; and p is 0 or 1; wherein optionally any two or more of R 4 , R 5 , or R 6 may be joined together to form one or more rings.

2 . The method of claim 1 , wherein the compound of Formula I is the compound of Formula I-11

or a pharmaceutically acceptable salt thereof.

Assignments (1)

Continuity (7)

References Cited (198)